Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV.
about
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV InfectionDynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineSystemic effects of inflammation on health during chronic HIV infectionCoagulation and morbidity in treated HIV infection.Immune activation and HIV persistence: considerations for novel therapeutic interventions.Residual immune dysregulation syndrome in treated HIV infection.Can early therapy reduce inflammation?Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infectionLong-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.HIV-Associated Venous ThromboembolismUsing the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities.Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation.HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levelsImmune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial.Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome.Vitamin D, D-dimer, Interferon γ, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International StudyCirculating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patientsMacrophages in Progressive Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections.Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trialHIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generationEvidence for innate immune system activation in HIV type 1-infected elite controllers.Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review.HIV and inflammation: mechanisms and consequences.Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.An Acute Abdominal Catastrophe in a HIV Positive PatientCardiovascular disease associated with the human immunodeficiency virus: an update.Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients.Embolizing Massive Right Atrial Thrombus in a HIV-Infected Patient
P2860
Q27024262-4DA46088-E6AE-451E-AE94-990E0683CD35Q27687272-36E9EAE6-075A-4997-8252-2564301B929EQ30245379-05D10A64-3E9D-4A14-96B0-2819B9E5FB27Q31146636-03F12CF4-90FA-402F-A2C0-848E8A1340FAQ33577551-002937F6-DF95-4683-BBF6-790FF8A63E0BQ33614424-577B3615-A3E7-42EE-96E4-E6C039F08258Q33698781-A7D907E2-4F5D-405E-993A-796ABA0D864AQ34020121-AA8C7AFD-C1C3-4CDD-8CE9-C7405EF5211AQ34159822-54A81585-CF44-44F3-9CC6-1BBEE018A166Q34396067-6A373093-9875-4C47-9172-7FCF41394FAAQ34452124-050AE2D4-6639-4852-BDBF-91784065CF48Q35153652-BBF6C41E-81F6-4DE9-A503-207D187CE04AQ35204909-9C6502DE-752C-4037-836E-9047A4775E85Q35655728-A148EFB0-AA0B-44DE-8275-038D074B468BQ35958319-9B86F06D-9F34-4903-AB25-466726DC1BF3Q36360872-AF340007-95ED-4953-8D28-3711D621ABBAQ36440077-31A22E3D-D727-4606-A867-2E441B62EC67Q36645092-3D956BA2-488F-4B9D-A88E-15AE30FB9BC0Q36930484-6FBB8623-9D8C-46EF-99D7-B6BFD20DADEBQ37182704-7FCBE27C-0054-4CDC-8898-59E4BCAA6734Q37213057-70AF272E-20C2-43FA-B0FB-A7932EE12892Q37310421-6854BACA-92EC-4374-8F11-DD374A054611Q37604465-1665C3BB-A923-4B70-83D5-3A8576F295E5Q37713159-AE26BFFE-A9E5-41C6-AB75-1A4B0381DB58Q38005046-68B2110C-B45E-4810-9484-0E15661422F4Q38603237-930A029D-21DD-458C-BA6B-70EA94EC2E10Q40507828-F6E5B733-F414-4FF1-9D3E-B74024AAD1A9Q41330412-9E886748-3EE0-41DF-90C4-25731C5DEB74Q41751842-584FC158-ABDE-4745-A680-5AE9C8545082Q42318292-27C564A6-E9B9-4E6E-9A99-9B4DFBE65A15Q57067023-1F3F353C-7563-4D51-BB10-7A72827AC90F
P2860
Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Markers of endothelial dysfunc ...... venous thromboembolism in HIV.
@ast
Markers of endothelial dysfunc ...... venous thromboembolism in HIV.
@en
type
label
Markers of endothelial dysfunc ...... venous thromboembolism in HIV.
@ast
Markers of endothelial dysfunc ...... venous thromboembolism in HIV.
@en
prefLabel
Markers of endothelial dysfunc ...... venous thromboembolism in HIV.
@ast
Markers of endothelial dysfunc ...... venous thromboembolism in HIV.
@en
P2093
P2860
P50
P921
P1433
P1476
Markers of endothelial dysfunc ...... venous thromboembolism in HIV.
@en
P2093
Adam Rupert
Brian O Porter
Colleen Hadigan
JoAnn M Mican
Scott R Penzak
Thomas D Norton
Virginia Sheikh
P2860
P304
P356
10.1097/QAD.0B013E3283453FCB
P407
P577
2011-03-01T00:00:00Z